AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.030
-0.110 (-3.50%)
At close: Feb 21, 2025, 4:00 PM
3.070
+0.040 (1.32%)
After-hours: Feb 21, 2025, 7:56 PM EST
AbCellera Biologics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for AbCellera Biologics stock have an average target of 8.00, with a low estimate of 4.00 and a high estimate of 12. The average target predicts an increase of 164.03% from the current stock price of 3.03.
Analyst Consensus: Buy
* Price targets were last updated on Jan 8, 2025.
Analyst Ratings
The average analyst rating for AbCellera Biologics stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy Maintains $5 → $4 | Buy | Maintains | $5 → $4 | +32.01% | Jan 8, 2025 |
| Benchmark | Benchmark | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 5, 2024 |
| Stifel | Stifel | Strong Buy Reiterates $14 → $12 | Strong Buy | Reiterates | $14 → $12 | +296.04% | Nov 5, 2024 |
| Benchmark | Benchmark | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Aug 20, 2024 |
| Keybanc | Keybanc | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +65.02% | Jul 11, 2024 |
Financial Forecast
Revenue This Year
32.21M
from 38.03M
Decreased by -15.29%
Revenue Next Year
44.21M
from 32.21M
Increased by 37.26%
EPS This Year
-0.61
from -0.51
EPS Next Year
-0.69
from -0.61
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 38.9M | 100.9M | 179.6M | |||
| Avg | 32.2M | 44.2M | 66.2M | |||
| Low | 27.6M | 18.6M | 29.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.2% | 213.3% | 306.2% | |||
| Avg | -15.3% | 37.3% | 49.8% | |||
| Low | -27.5% | -42.2% | -32.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -0.57 | -0.47 | -0.41 | |||
| Avg | -0.61 | -0.69 | -0.62 | |||
| Low | -0.63 | -0.83 | -0.75 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.